Paediatric use of second-line anti-tuberculosis agents: a review.
about
Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected childrenClinical peculiarities of tuberculosisMap the gap: missing children with drug-resistant tuberculosisAssessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative studyGetting to 90-90-90 in paediatric HIV: What is needed?Pediatric Tuberculosis in Italian Children: Epidemiological and Clinical Data from the Italian Register of Pediatric Tuberculosis.Tuberculosis and pneumonia in HIV-infected children: an overviewIncidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimatesControversies in preventive therapy for children contacts of multidrug-resistant tuberculosis.Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospectsTowards early inclusion of children in tuberculosis drugs trials: a consensus statementAdvances in Drug Discovery and Development for Pediatric Tuberculosis.Caring for children with drug-resistant tuberculosis: practice-based recommendations.Dilemma of managing asymptomatic children referred with 'culture-confirmed' drug-resistant tuberculosisChanging prevalence and resistance patterns in children with drug-resistant tuberculosis in Mumbai.Commentary: a targets framework: dismantling the invisibility trap for children with drug-resistant tuberculosis.The spread of drug-resistant tuberculosis in children: an Italian case series.Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study.Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience.Drug-Resistant Tuberculosis among Children, China, 2006-2015.Reply to Seddon, Schaaf, and Hesseling.Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.
P2860
Q26774267-A77D95E6-A19F-4A95-9937-1B7D087CE9B8Q27009986-0E790D8A-12E3-48F1-864F-562F1848C05CQ28547002-83165884-836A-4B21-89AD-BAA7164BB6C7Q28654702-6EDA9EF8-B3F7-472F-8FDE-EBA5FA2A8CBBQ30385352-CBF9D2A6-1215-4473-B147-A0D62DE8F8F7Q31109156-9481F7ED-088D-4B76-8970-F0543E84E3CAQ33801297-BFE10C1A-9830-4F6B-B16F-8A2E95B26FE3Q33889335-5C26C4A6-01A2-4180-AD9A-3F954AD7902DQ35007404-06BDB166-DDE9-4841-BE30-1743C0C2BDC6Q35197235-F629ABE0-C07A-4915-B974-907AD499978AQ35752740-5140BCCA-923D-45DA-931D-68C8949E1F59Q37134041-9D95977F-ACE4-41E6-8932-F5EC863905DBQ38043978-76178CD6-C99A-4F3A-92DA-EBC7F73FA51AQ38797948-5739DF50-EE1A-44FE-B625-7B221C048238Q40522564-BF092275-AFD5-4CC4-8B0C-726ABF919246Q41744320-E7A57CD4-E066-4697-BD39-BDED6E9F0F10Q42230437-FB398933-6347-4303-BBE1-2EB3D3D14FA3Q42246655-202FCC94-65F5-4AC6-988E-EFBD5185E20AQ42275450-38327F0C-84E4-47B8-84D1-475AC3218862Q42650309-7A6155D8-CB2F-40D4-92B8-2D9AA5034FEEQ42927067-756CC737-D974-4FAE-B43A-E9E16AE24447Q46895816-E4FD2365-4024-4BBD-89AB-95EE6EB94F35
P2860
Paediatric use of second-line anti-tuberculosis agents: a review.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Paediatric use of second-line anti-tuberculosis agents: a review.
@en
Paediatric use of second-line anti-tuberculosis agents: a review.
@nl
type
label
Paediatric use of second-line anti-tuberculosis agents: a review.
@en
Paediatric use of second-line anti-tuberculosis agents: a review.
@nl
prefLabel
Paediatric use of second-line anti-tuberculosis agents: a review.
@en
Paediatric use of second-line anti-tuberculosis agents: a review.
@nl
P2093
P1433
P1476
Paediatric use of second-line anti-tuberculosis agents: a review.
@en
P2093
Anneke C Hesseling
Ben J Marais
Charles A Peloquin
H Simon Schaaf
Peter R Donald
P356
10.1016/J.TUBE.2011.11.001
P577
2011-11-25T00:00:00Z